Genpact's 3-Cent EPS Beat Won't Matter Unless This Revenue Miss Is Temporary

Genpact Q2: a small EPS beat could not hide the revenue miss

Genpact's latest quarter looks better on earnings than on sales. Q2 revenue came in at $1.343 billion versus roughly $1.38 billion consensus, a miss of about $37 million. Adjusted EPS of $1.00 beat the 97-cent consensus, but the three-cent earnings surprise looks thin against the top-line shortfall. In other words, Genpact showed discipline and reasonably healthy mix, but still did not convince the market that demand is firm.

The market has already shown what it cares about

Last quarter, Genpact reported impressive first-quarter 2026 results, yet investors focused on weak second-quarter revenue guidance and the stock fell 9.4% after the release. Today's reaction risk is similar: another modest EPS beat matters less if investors think the revenue pipeline is still soft.

That is why the next few quarters matter more than this one. As the current evidence shows, Genpact still has some support from record bookings and backlog. If Q3 lands near guide, this quarter's revenue miss may look like a stumble. If it does not, the stock will keep trading around the same demand question.

Genpact's growth is shifting toward ATS, but the core still drags

The more balanced read is that Genpact's growth is shifting rather than fading. The fastest part of the business remains strong: Advanced Technology Solutions was up 24.1% in Q2 and now accounts for 27% of total revenue. That followed Q1, when ATS accelerated to 24% and was already 27% of total net revenues. Management has also linked demand to data, AI and agentic solutions.

Investors do not need all of Genpact's revenue to come from AI-related work. They just need the higher-value segment to keep expanding fast enough to change how the market values the company.

The bull case: the mix shift still has credibility

The bullish case is straightforward. ATS is still growing well above the rest of the business, and that matters because it can lift the quality of revenue over time. If that momentum persists, Genpact can keep making the case that it is becoming more than a mature back-office services platform.

The bear case: the slower base still limits the story

The bearish case is just as easy to understand. If the growth engine were fully warming up, why did revenue miss again? The issue is not ATS itself. The issue is that the slower part of the portfolio still weighs on the total. In Q1, Core Business Services revenues increased 1.4% year over year to $951 million and accounted for 73% of total revenues. As long as the faster segment is not large enough to offset the slower base, one weak quarter can look less like noise and more like a softening top line.

Cash flow is the other watchpoint. In Q1, Genpact posted adjusted EBITDA of $238.6 million versus estimates of $242.9 million and free cash flow of -$54.98 million. Profit per share can be supported by cost control. It is much harder to support a weaker revenue trend with accounting discipline alone.

What has to happen in Q3 for the stock to regain confidence

The next print needs to answer one question: was Q2 an anomaly, or the start of a softer demand pattern?

The near-term scorecard

Genpact has set a clear bar. It sees Q3 revenue of $1.369 billion to $1.382 billion versus roughly $1.38 billion consensus, and Q3 adjusted EPS of $1.04 to $1.05 versus about $1.05 consensus. The market does not need a miracle here. It needs proof that the revenue miss was temporary.

Key watchpoints

• Guidance credibility: hitting even the low end of the Q3 revenue range would suggest Genpact can get back on track after a below-plan Q2.
• EPS durability: the $1.04 to $1.05 EPS outlook assumes margins can hold, but that still depends on demand following through.
• Mix conversion: Genpact already showed ATS net revenue growth accelerating to 24% earlier this year, and record bookings and backlog support at least 7% revenue growth and 25% ATS growth for 2026. The next quarter has to show that pipeline turning into steady revenue.

This is still more of a watchlist setup than a blind dip-buy. If Genpact clears that bar again, investors can reasonably re-engage. If not, the stock will likely keep trading as a good operator with an unresolved demand question.